<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SUCRALFATE- sucralfateÂ tabletÂ </strong><br>Mylan Institutional Inc.<br></p></div>
<h1>
<span class="Bold">SUCRALFATE TABLETS, USP</span><br><span class="Bold">Rx only</span><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_f3371396-ea6b-41d3-8896-f48a275997ff"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sucralfate, USP is an Î±-D-glucopyranoside, Î²-D-fructofuranosyl-, octakis(hydrogen sulfate), aluminum complex.</p>
<div class="Figure">
<a name="id217"></a><img alt="Structural formula for sucralfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=989ca8a8-3ad6-4ee4-aa9c-eed731828753&amp;name=4db8cb98-4335-464d-a3f1-1045f5e6f86b-01.jpg">
</div>
<p>R = SO<span class="Sub">3</span>Al(OH)<span class="Sub">2</span></p>
<p>Tablets for oral administration contain 1 g of sucralfate, USP and the following inactive ingredients: corn starch, magnesium stearate, and microcrystalline cellulose.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_32114920-5d8e-4cc4-ad72-6876cc61b7e9"></a><a name="section-1.1"></a><p></p>
<h2>Therapeutic Category</h2>
<p class="First">antiulcer</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_cab8ef65-6126-4a61-89d5-32cb8901fc07"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.</p>
<p>Although the mechanism of sucralfateâ€™s ability to accelerate healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent:</p>
<dl>
<dt>1.</dt>
<dd>Studies in human subjects and with animal models of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease have shown that sucralfate forms an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>-adherent complex with proteinaceous exudate at the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> site.</dd>
<dt>2.</dt>
<dd>
<span class="Italics">In vitro</span>, a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions.</dd>
<dt>3.</dt>
<dd>In human subjects, sucralfate given in doses recommended for <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> therapy inhibits pepsin activity in gastric juice by 32%.</dd>
<dt>4.</dt>
<dd>
<span class="Italics">In vitro</span>, sucralfate adsorbs bile salts.</dd>
</dl>
<p>These observations suggest that sucralfateâ€™s antiulcer activity is the result of formation of an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>-adherent complex that covers the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_abe1f43f-2a61-497d-bdef-f9e862a536ee"></a><a name="section-3"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cc050571-bf22-42f7-a07b-752e338e59cd"></a><a name="section-3.1"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></h2>
<p class="First">Over 600 patients have participated in well-controlled clinical trials worldwide. Multicenter trials conducted in the United States, both of them placebo-controlled studies with endoscopic evaluation at 2 and 4 weeks, showed:</p>
<a name="_Refid_1bb06564-f1f9-4fc2-b91d-1638d2565"></a><table width="100%">
<caption><span>STUDY 1</span></caption>
<col width="31%">
<col width="31%">
<col width="38%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">Treatment Groups</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Healing/No. Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"> Â  </p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">2 wk</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">4 wk (Overall)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> Sucralfate </p></td>
<td class="Botrule" align="center"><p class="First"> 37/105 (35.2%) </p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 82/109 (75.2%) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"> Placebo </p></td>
<td class="Botrule" align="center"><p class="First"> 26/106 (24.5%) </p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 68/107 (63.6%) </p></td>
</tr>
</tbody>
</table>
<a name="_Refid_cd8a135c-b3a8-4d29-9805-0bfd2269c"></a><table width="100%">
<caption><span>STUDY 2</span></caption>
<col width="31%">
<col width="31%">
<col width="38%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">Treatment Groups</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Healing/No. Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> Â  </p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">2 wk</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">4 wk (Overall)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> Sucralfate </p></td>
<td class="Botrule" align="center"><p class="First"> 8/24 (33%) </p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 22/24 (92%) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"> Placebo </p></td>
<td class="Botrule" align="center"><p class="First"> 4/31 (13%) </p></td>
<td class="Botrule Rrule" align="center"><p class="First"> 18/31 (58%) </p></td>
</tr>
</tbody>
</table>
<p>The sucralfate-placebo differences were statistically significant in both studies at 4 weeks but not at 2 weeks. The poorer result in the first study may have occurred because sucralfate was given 2 hours after meals and at bedtime rather than 1 hour before meals and at bedtime, the regimen used in international studies and in the second United States study. In addition, in the first study liquid antacid was utilized as needed, whereas in the second study antacid tablets were used.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec3d5a34-b896-4948-b3b0-34b1ebf73954"></a><a name="section-3.2"></a><p></p>
<h2>Maintenance Therapy After Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></h2>
<p class="First">Two double-blind randomized placebo-controlled U.S. multicenter trials have demonstrated that sucralfate (1 g bid) is effective as maintenance therapy following healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>.</p>
<p>In one study, endoscopies were performed monthly for 4 months. Of the 254 patients who enrolled, 239 were analyzed in the intention-to-treat life table analysis presented below.</p>
<a name="_Refid_b3bf84c0-6088-4814-afcc-547f592cf"></a><table width="100%">
<caption><span><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence Rate (%)</span></caption>
<col width="22%">
<col width="17%">
<col width="19%">
<col width="15%">
<col width="14%">
<col width="14%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>p &lt; 0.05</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>p &lt; 0.01</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="6" valign="middle"><p class="First"><span class="Bold">Months of Therapy</span></p></td></tr>
<tr>
<td class="Botrule" valign="middle"><p class="First"><span class="Bold">Drug</span></p></td>
<td class="Botrule" valign="middle"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule" valign="middle"><p class="First"><span class="Bold">1</span></p></td>
<td class="Botrule" valign="middle"><p class="First"><span class="Bold">2</span></p></td>
<td class="Botrule" valign="middle"><p class="First"><span class="Bold">3</span></p></td>
<td class="Botrule" valign="middle"><p class="First"><span class="Bold">4</span></p></td>
</tr>
<tr>
<td class="Botrule" valign="middle"><p class="First">Sucralfate</p></td>
<td class="Botrule" valign="middle"><p class="First">122</p></td>
<td class="Botrule" valign="middle"><p class="First">20<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule" valign="middle"><p class="First">30<a href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule" valign="middle"><p class="First">38<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a></p></td>
<td class="Botrule" valign="middle"><p class="First">42<a href="#footnote-2" class="Sup">â€ </a></p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"><p class="First">Placebo</p></td>
<td class="Botrule" valign="middle"><p class="First">117</p></td>
<td class="Botrule" valign="middle"><p class="First">33</p></td>
<td class="Botrule" valign="middle"><p class="First">46</p></td>
<td class="Botrule" valign="middle"><p class="First">55</p></td>
<td class="Botrule" valign="middle"><p class="First">63</p></td>
</tr>
</tbody>
</table>
<p>In this study, prn antacids were not permitted.</p>
<p>In the other study, scheduled endoscopies were performed at 6 and 12 months, but for-cause endoscopies were permitted as symptoms dictated. Median symptom scores between the sucralfate and placebo groups were not significantly different. A life table intention-to-treat analysis for the 94 patients enrolled in the trial had the following results:</p>
<a name="_Refid_d2251d56-1ac4-4f00-90ed-6b2baac34"></a><table width="100%">
<caption><span><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence Rate (%)</span></caption>
<col width="27%">
<col width="19%">
<col width="27%">
<col width="28%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>p &lt; 0.002</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="middle"><p class="First"><span class="Bold">Drug</span></p></td>
<td class="Botrule Toprule" valign="middle"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Toprule" valign="middle"><p class="First"><span class="Bold">6 months</span></p></td>
<td class="Botrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">12 months</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">Sucralfate</p></td>
<td class="Botrule" valign="middle"><p class="First">48</p></td>
<td class="Botrule" valign="middle"><p class="First">19<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">27<a href="#footnote-3" class="Sup">*</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="middle"><p class="First">Placebo</p></td>
<td class="Botrule" valign="middle"><p class="First">46</p></td>
<td class="Botrule" valign="middle"><p class="First">54</p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">65</p></td>
</tr>
</tbody>
</table>
<p>In this study, prn antacids were permitted.</p>
<p>Data from placebo-controlled studies longer than 1 year are not available.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_4ead96da-b978-43b7-87c0-e9b259d008fc"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Sucralfate tablets, USP are indicated in:</p>
<dl>
<dt>â€¢</dt>
<dd>Short-term treatment (up to 8 weeks) of active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.</dd>
<dt>â€¢</dt>
<dd>Maintenance therapy for <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> patients at reduced dosage after healing of acute <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_5d2bc0ff-db65-474b-b4a2-00439bf6f358"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Sucralfate tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to the active substance or to any of the excipients.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_29c85200-3eb5-48d1-aa5b-88095a2f26f9"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">The physician should read the <span class="Bold">PRECAUTIONS</span> section when considering the use of this drug in pregnant or pediatric patients, or patients of childbearing potential.</p>
<p><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal ulcer</span> is a chronic, recurrent disease. While short-term treatment with sucralfate can result in complete healing of the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, a successful course of treatment with sucralfate should not be expected to alter the post healing frequency or severity of duodenal ulceration.</p>
<p>Isolated reports of sucralfate tablet <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> with accompanying respiratory complications have been received. Therefore, sucralfate tablets should be used with caution by patients who have known conditions that may impair swallowing, such as recent or prolonged intubation, tracheostomy, prior history of <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, or any other conditions that may alter gag and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflexes, or diminish oropharyngeal coordination or motility.</p>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_a8690fbc-dfb6-47e6-87c8-34df2b3a4454"></a><a name="section-6.1"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_72cf79a4-6a2a-41d8-ab6f-1b0365c70490"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">Chronic Renal Failure</span> and Dialysis Patients</span></h3>
<p class="First">When sucralfate is administered orally, small amounts of aluminum are absorbed from the gastrointestinal tract. Concomitant use of sucralfate with other products that contain aluminum, such as aluminum-containing antacids, may increase the total body burden of aluminum. Patients with normal renal function receiving the recommended doses of sucralfate and aluminum-containing products adequately excrete aluminum in the urine. Patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> or those receiving dialysis have impaired excretion of absorbed aluminum. In addition, aluminum does not cross dialysis membranes because it is bound to albumin and transferrin plasma proteins. Aluminum accumulation and toxicity (aluminum <span class="product-label-link" type="condition" conceptid="75924" conceptname="Osteodystrophy">osteodystrophy</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>) have been described in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Sucralfate should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_83482246-8e44-4433-be3d-302664e02241"></a><a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time with the addition of sucralfate to chronic warfarin therapy.</p>
<p>The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. Because of the potential of sucralfate to alter the absorption of some drugs, sucralfate should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_6872be7e-a2ab-48f8-9431-ecffca773bf2"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Chronic oral toxicity studies of 24 monthsâ€™ duration were conducted in mice and rats at doses up to 1 g/kg (12 times the human dose). </p>
<p>There was no evidence of drug-related tumorigenicity. A reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. Mutagenicity studies were not conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_963c68bd-ab29-444b-a05a-d1c9cfdccf92"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_2a12f465-0115-4562-aebc-73729d26802f"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_130f9915-81aa-44f3-a2e1-a8eb6f2685f0"></a><a name="section-6.4.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy category B</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to sucralfate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_658343a1-30b5-451b-880c-baf3a4b670be"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sucralfate is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_fe3a8980-b0cc-4d07-97ec-10e9a64ad1f8"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_4e519694-e89d-4730-ad68-7290d33e628f"></a><a name="section-6.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of sucralfate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see <span class="Bold">DOSAGE ANDADMINISTRATION</span>).</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <span class="Bold">PRECAUTIONS</span>, <span class="Bold">SpecialPopulations</span>, <span class="Italics">Chronic Renal Failureand Dialysis Patients</span>). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_31a39a9d-d1d6-4c7f-aa97-bb93b2fdace2"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%).</p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_35fa034c-83dd-4905-9c21-2630ad4e5c0a"></a><a name="section-7.1"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gastric <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82c64a41-839b-4575-9178-d9d570a3d0df"></a><a name="section-7.2"></a><p></p>
<h2>Dermatological</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49662067-319d-4496-a4d4-72e296dd98b0"></a><a name="section-7.3"></a><p></p>
<h2>Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9067ccb0-e66c-4c10-8e65-c684328543a9"></a><a name="section-7.4"></a><p></p>
<h2>Other</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p>Postmarketing cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been reported with the use of sucralfate tablets, including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">lip swelling</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. </p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the mouth, <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>, respiratory tract <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face have been reported with an unknown oral formulation of sucralfate.</p>
<p><span class="product-label-link" type="condition" conceptid="4198551" conceptname="Bezoar">Bezoars</span> have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to <span class="product-label-link" type="condition" conceptid="4198551" conceptname="Bezoar">bezoar</span> formation (such as <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">delayed gastric emptying</span>) or were receiving concomitant enteral tube feedings.</p>
<p>Inadvertent injection of insoluble sucralfate and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli. Sucralfate is <span class="Bold">not</span> intended for intravenous administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_612bd03d-74e4-4efc-ac2f-69e36046d526"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Due to limited experience in humans with overdosage of sucralfate, no specific treatment recommendations can be given. Acute oral toxicity studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. Sucralfate is only minimally absorbed from the gastrointestinal tract. Risks associated with acute overdosage should, therefore, be minimal. In rare reports describing sucralfate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5d2f675e-f127-45fc-8b5a-74ac553ca63a"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ef415471-c6c7-4253-a23e-410d814c9327"></a><a name="section-9.1"></a><p></p>
<h2>Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></h2>
<p class="First">The recommended adult oral dosage for <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> is 1 g four times per day on an empty stomach.</p>
<p>Antacids may be prescribed as needed for relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> but should not be taken within one-half hour before or after sucralfate.</p>
<p>While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ab5ac34-0b92-48b8-8c11-2e0ab8939073"></a><a name="section-9.2"></a><p></p>
<h2>Maintenance Therapy</h2>
<p class="First">The recommended adult oral dosage is 1 g twice a day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dc449681-c91f-4e69-8a31-ec9122f3aa79"></a><a name="section-9.3"></a><p></p>
<h2>Elderly</h2>
<p class="First">In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see <span class="Bold">PRECAUTIONS</span>, <span class="Bold">Geriatric Use</span>).</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to TEVA USA, PHARMACOVIGILANCE at tel: 1-888-838-2872, x6351 or <a href="http://mailto:drug.safety@tevapharm.com">drug.safety@tevapharm.com</a>; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_1cfd947a-4f16-4d3c-b7a0-a755be283c77"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Sucralfate tablets, USP are available as white, capsule-shaped, biconvex, scored tablets, debossed â€œTEVAâ€? on one side, and â€œ22â€? and â€œ10â€? on the scored side, containing 1 gram of sucralfate USP.<br>They are available as follows:</p>
<p>NDC 51079-753-20 â€“ Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 100 (10 cards of 10 tablets each).</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</span></p>
<p>Manufactured in Croatia by:<br><span class="Bold">Pliva Hrvatska d.o.o.</span><br>Zagreb, Croatia</p>
<p>Manufactured for: <br><span class="Bold">Teva Pharmaceuticals USA</span><br>Sellersville, PA 18960</p>
<p>Distributed by:<br><span class="Bold">Mylan Institutional Inc.</span><br>Rockford, IL 61103 U.S.A.</p>
<p>S-11970<br>9/13</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bb1c45f0-3a7b-4103-8141-582341256f3f"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 1 gram</h1>
<p class="First">NDC 51079-753-20</p>
<p><span class="Bold">Sucralfate<br>Tablets, USP<br>1 gram</span></p>
<p>100 Tablets (10 x 10)</p>
<p>Each tablet contains 1 gram<br>sucralfate, USP.</p>
<p><span class="Bold">Usual Dosage:</span>  See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See<br>USP Controlled Room Temperature.]</span></p>
<p>Manufactured in Croatia by:<br><span class="Bold">Pliva Hrvatska d.o.o.</span><br>Zagreb, Croatia</p>
<p>Manufactured for:<br><span class="Bold">Teva Pharmaceuticals USA</span><br>Sellersville, PA 18960</p>
<p><span class="Bold">Rx only</span></p>
<p>S-11974</p>
<p>Packaged and Distributed by:</p>
<p><span class="Bold">Mylan Institutional Inc.</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>This unit dose package is not child resistant.</p>
<p>For institutional use only.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<p>This container provides light-resistance.</p>
<p>See window for lot number and expiration date.</p>
<div class="Figure">
<a name="id-440686589"></a><img alt="Sucralfate 1 gram Tablet Unit Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=989ca8a8-3ad6-4ee4-aa9c-eed731828753&amp;name=image-01.jpg">
</div>
<div class="Figure">
<a name="id864484447"></a><img alt="Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=989ca8a8-3ad6-4ee4-aa9c-eed731828753&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SUCRALFATEÂ 		
					</strong><br><span class="contentTableReg">sucralfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51079-753</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SUCRALFATE</strong> (SUCRALFATE) </td>
<td class="formItem">SUCRALFATE</td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TEVA;22;10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-753-20</td>
<td class="formItem">100  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-753-01</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070848</td>
<td class="formItem">09/24/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Institutional Inc.
							(039615992)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>989ca8a8-3ad6-4ee4-aa9c-eed731828753</div>
<div>Set id: 989ca8a8-3ad6-4ee4-aa9c-eed731828753</div>
<div>Version: 1</div>
<div>Effective Time: 20130906</div>
</div>
</div>Â <div class="DistributorName">Mylan Institutional Inc.</div></p>
</body></html>
